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The totality of glycans produced by cells, referred to as the
glycome, is a dynamic indicator of the cell’s physiology.
1 The
glycome changes as a function of developmental stage, cellular
activation, and transformation from a healthy to a pathological state
(e.g., cancer).
2 Molecular imaging of the glycome promises to
advance our understanding of these processes and their implications
in the diagnosis and treatment of disease.
3 The notion of imaging
glycans in ViVo was recently enabled by the bioorthogonal chemical
reporter technique.
4 First, a sugar analogue adorned with a
bioorthogonal functional group is metabolically incorporated into
cellular glycans. In a second step, the modiﬁed sugar is chemically
reacted with an exogenously added imaging probe bearing comple-
mentary functionality.
This method of visualizing glycans was ﬁrst developed in the
context of cultured cells, using azidosugars as metabolic labels and
the Staudinger ligation with phosphines as a means to introduce
ﬂuorescence imaging probes.
5 Since then, other chemistries have
been explored, including Cu-catalyzed cycloaddition of metaboli-
cally incorporated alkynyl sugars with azide-functionalized ﬂuo-
rophores (i.e., click chemistry)
6 and strain-promoted cycloaddition
of azidosugars with cyclooctyne probes (i.e., Cu-free click chem-
istry).
7 The suitability of these chemistries for various imaging
applications reﬂects a balance of attributes, including intrinsic
kinetic parameters, reagent toxicity, and bioavailability. With respect
to kinetics, the Cu-catalyzed azide-alkyne cycloaddition (CuAAC)
has a signiﬁcant advantage over the Staudinger ligation.
8 However,
the cytotoxicity of the Cu(I) catalyst disqualiﬁes this chemistry from
use with live cells or organisms.
9 Diﬂuorinated cyclooctyne (DIFO)
probes have fast kinetics and no observable toxicity; consequently,
they were used for the ﬁrst in ViVo imaging study of glycans in
developing zebraﬁsh.
10 However, in mice, the most common animal
model of human disease, DIFO probes appear to have limited
bioavailability.
11 Thus, despite their superior kinetic parameters,
DIFO probes label cell-surface azidosugars less efﬁciently than
phosphine reagents in this model organism.
To date, phosphines remain the best-performing reagents for
tagging azidosugars in mice, but their slow reaction kinetics
mandates the use of high concentrations in ViVo. With ﬂuorescent
probes, this situation leads to high background labeling and low
signal-to-noise ratios. While ﬂuorogenic “smart” phosphines can
partially mitigate the problem,
12 the complexity of such probes, as
well as sensitivity issues caused by tissue autoﬂuorescence, has
undermined efforts to image glycans in mice using ﬂuorescent
phosphine reagents.
Bioluminescence imaging (BLI)
13 obviates many of the
intrinsic limitations of ﬂuorescence imaging with phosphine
probes. The technique is based on the sensitive detection of
visible light produced during enzyme (luciferase)-mediated
oxidation of a small molecule substrate (luciferin) when the
enzyme is expressed as a reporter. BLI is gaining appreciation
for its use in real-time animal imaging, as the total absence of
tissue luminescence bestows negligible background, enabling
exquisite sensitivity.
14 Many types of luciferase transgenic mice
as well as disease speciﬁc models are now commercially
available. Since BLI is dependent on the presence of luciferase,
transfected cells or transgenic animals are required for the
experiments. Thus, clinical translation is not possible; however,
this technique still represents a powerful tool to answer basic
research questions. We reasoned that a phosphine-luciferin
conjugate (1, Figure 1) designed to release luciferin upon
Staudinger ligation would enable sensitive detection of azidosugars
with very low background signal, even when the reagent was
employed at relatively high concentrations (e.g., in the micromolar
range). Further, the intrinsic sensitivity of BLI might enable the
use of lower phosphine probe concentrations than were found to
be required for ﬂuorescence imaging (e.g., in the nanomolar range).
Here we report the synthesis of compound 1 and its use in real-
time BLI of azidosugars on live cells.
Compound 1 comprises ﬁreﬂy luciferin linked to triphenylphos-
phine through a carboxy ester that is cleaved during Staudinger
ligation with an azide.
15 Compound 1 itself cannot produce
bioluminescence due to the esteriﬁed phenolic oxygen, a modiﬁca-
tion that disrupts recognition of luciferin by luciferase.
16 Thus, only
luminescence due to ﬁreﬂy luciferin released during the Staudinger
ligation is observed. The synthesis of 1 is outlined in Scheme 1
and described in detail in the Supporting Information (SI).
Figure 1. Use of 1 for bioluminescence imaging of cell-surface azidosugars.
Compound 1 releases ﬁreﬂy luciferin upon Staudinger ligation with azides.
After luciferin diffuses into cells, luciferase-catalyzed conversion of luciferin
to oxyluciferin is accompanied by production of a photon of light, which
is detected using a CCD camera.
Scheme 1. Synthesis of Phosphine-Luciferin Conjugate 1
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uncouple luciferin release from the Staudinger ligation, thereby
undermining 1’s design. Thus, we probed the rates of the two
processes in model reactions. Using benzyl azide as a substrate in
acetonitrile/water (19:1), Staudinger ligation with 1 proceeded with
a second-order rate constant of 2.3 × 10-3 M-1s -1 (SI, Figure
S1), a value similar to those found for previously studied phosphine
substrates.
15 In the context of in ViVo cell-surface labeling, this
number translates into reaction times in the range of 1-2ht o
achieve conversion of a majority of azides.
17 Hydrolysis of 1 in
cell culture media containing physiological glutathione occurred
with a half-life of ∼5 days (see SI). Thus, 1 possesses sufﬁcient
hydrolytic stability for our envisioned application.
To evaluate 1’s performance in cell-surface azidosugar imaging,
we employed a prostate cancer cell line stably transfected with
ﬁreﬂy luciferase (LNCaP-luc). We chose this cell line because it
was one of the most robust with respect to azidosugar incorpora-
tion.
18 The cells were incubated for 2 days with various concentra-
tions of peracetylated N-azidoacetylmannosamine (Ac4ManNAz)
or peracetylated N-azidoacetylgalactosamine (Ac4GalNAz) (10, 35,
or 50 µM) to allow for metabolic incorporation of N-azido sialic
acid (SiaNAz)
19 and GalNAz
20 into sialylated and mucin-type
O-glycans, respectively. Control cells were incubated in media that
did not contain azidosugars. In addition, we incubated cells with
peracetylated N-azidoacetylglucosamine (Ac4GlcNAz), which is
incorporated into nuclear and cytosolic proteins but not, to any
appreciable extent, into cell-surface glycans.
20,21 After several
washes to remove all exogenous azidosugars in the media, the cells
were incubated with various concentrations of 1 (ranging from 3
nM to 100 µM), and the number of photons produced as a function
of time was quantiﬁed using a charge-coupled device camera.
Cells incubated with Ac4ManNAz or Ac4GalNAz and 1 showed
signiﬁcantly higher luminescence than control cells lacking azi-
dosugars (Figure 2). Also, the signal was proportional to the
concentration of azidosugar (Figure 2) and the probe (Figure 4).
Figure 2 shows the total bioluminescence produced by cells treated
with each azidosugar. Figure S2 in the SI depicts the real-time signal
produced from cells treated with different concentrations of
Ac4ManNAz. Cells treated with Ac4GlcNAz showed the same
background level of bioluminescence as cells treated with no
azidosugar. Collectively, these results indicate that the observed
signal above background is due to luciferin released during the
Staudinger ligation with cell-surface azidosugar.
Given the hydrophobic nature of 1, we questioned whether the
luminescence observed was due to Staudinger ligation at the cell
surface, or, following passive diffusion into the cell, reaction with
intracellular azido-metabolic intermediates. We therefore treated
cells labeled with each azidosugar with sialidase to cleave cell-
surface sialic acids.
22 This treatment was expected to reduce the
number of azides present on cells incubated with Ac4ManNAz but
have a negligible effect on cells incubated with the other two
azidosugars.
17 After reaction with 1 and subsequent imaging, we
observed a signiﬁcant decrease in the number of photons produced
from Ac4ManNAz-labeled cells treated with sialidase as compared
to Ac4ManNAz-labeled cells having no sialidase treatment (Figure
3). The ∼60% reduction in signal observed with sialidase-treated
cells agrees well with previous studies using other detection
methods.
22 In contrast, the number of photons produced by
Ac4GalNAz- or Ac4GlcNAz-labeled cells was unaffected by siali-
dase treatment. These results indicate that the observed lumines-
cence largely reﬂects Staudinger ligation with cell-surface azi-
dosugars.
We noted that cells without azidosugar treatment displayed low
levels of bioluminescence upon treatment with 1. Chemical
hydrolysis seemed an unlikely explanation given the time scale of
the experiments (1-3 h). We therefore tested the hypothesis that
esterases produced by the cells or in residual serum from cell culture
media were catalyzing the hydrolysis of 1. Prior to the addition of
1, LNCaP-luc cells were treated with sodium ﬂuoride (NaF),
phenylmethylsulfonyl ﬂuoride (PMSF), or 5,5′-dithiobis-2-nitroben-
zoic acid (DTNB), inhibitors of carboxyesterases, serine esterases,
and aryl esterases, respectively.
23 DTNB treatment reduced the
luminescence signal ∼3-fold, whereas the other two inhibitors had
no signiﬁcant effect (SI, Figure S3). Thus, aryl esterase activities
may contribute to background luminescence.
BLI has the intrinsic potential for very high sensitivity compared
to other optical imaging modalities. For 1 to realize this potential,
the BLI signal produced by Staudinger ligation with azidosugars
must exceed background luminescence derived from ester hydroly-
Figure 2. Labeling of cell-surface azidosugars with phosphine-luciferin
1. LNCaP-luc cells, a prostate cancer cell line stably transfected with
luciferase, were incubated for 2 days in the presence of various concentra-
tions of Ac4ManNAz, Ac4GalNAz, Ac4GlcNAz, or media. The cells were
washed three times with 200 µL of PBS and then treated with 1 (100 µM)
for 120 min. The total bioluminescence was obtained by calculating the
area under the curves represented by those in Figure S2 (SI). Error bars
represent the standard deviation of the mean for three replicate experiments.
Figure 3. Sialidase treatment reduces labeling seen with 1. LNCaP-luc
cells were incubated for 2 days in the presence of 50 µMA c 4ManNAz,
Ac4GalNAz, Ac4GlcNAz, or media. Cells were treated with Arthrobacter
ureafaciens sialidase (patterned bars) or left untreated (black bars). The
cells were then treated with 1 (100 µM) for 1 h, and the total biolumines-
cence was quantiﬁed. Error bars represent the standard deviation of the
mean for three replicate experiments.
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sensitivity of 1, we incubated Ac4ManNAz-treated cells with doses
of 1 ranging from 3 nM to 100 µM, and collected photons at time
points from 5 to 200 min. Signiﬁcant azide-speciﬁc luminescence
above background was observed at all concentrations of 1 (Figure
4) and with as little as 5 min of photon collection (SI, Figure S4).
As expected, the signal-to-background ratio increased with probe
concentration, with a maximal value of ∼10 observed at 50-100
µM. These results contrast markedly with our previous observations
using ﬂuorescent-phosphine probes. In those studies, the minimum
probe concentrations required to observe speciﬁc signal above
background labeling were ∼10 µM.
5 Therefore, BLI with 1 appears
to exceed the sensitivity of its ﬂuorescence counterpart by several
orders of magnitude, even when accounting for background
luminescence derived from ester hydrolysis.
Looking ahead, 1 is a promising reagent for in ViVo imaging of
azide-labeled glycans. Improvements can be envisioned, the most
obvious of which is redesign of the compound to mitigate enzymatic
hydrolysis. How relevant this issue will be in the context of live
animal imaging remains to be determined. Even in its present form,
1 enables real-time imaging of cell-surface glycans with unprec-
edented sensitivity using very low probe concentrations. Since other
biomolecules can be metabolically labeled with azido precursors
4s
lipids, proteins, and nucleic acids to name a fewsBLI with 1 may
represent a new platform for real-time imaging of numerous cellular
processes. Even though we have only demonstrated its use in
visualizing glycans, it can be envisioned that this probe could also
be used for these applications.
4,24 Bioluminescence imaging with
1 will thus be a useful tool for answering many fundamental
biological questions. Studies with 1 in both healthy mice and cancer
models are currently underway.
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Figure 4. Sensitivity of labeling of SiaNAz with 1. LNCaP-luc cells were
incubated for 2 days in the presence of 50 µMA c 4ManNAz (9) or media
(b). The cells were washed three times with PBS and then treated with 1
for 30 min. For each concentration, the total bioluminescence was quantiﬁed
over 30 min. Error bars represent the standard deviation of the mean for
three replicate experiments.
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